A Landmark Offer to Close a Long Legal Battle
Johnson & Johnson has proposed paying up to $5.5 billion to settle tens of thousands of lawsuits alleging that its talcum powder products caused ovarian cancer — a move that would bring near-final resolution to one of the most protracted product-liability battles in American corporate history [1].
The New Jersey-based healthcare giant said the proposed settlement would cover approximately 69,000 cases, representing the bulk of remaining talc-related claims in both state and federal courts [1]. The company stressed, however, that it continues to deny any wrongdoing.
What the Settlement Would Look Like
Under the terms J&J outlined, the company would offer up to $3 billion in the first payment next year, with no additional disbursements required before 2028 [1]. The deal is not yet final: it must be accepted by law firms representing at least 95% of the ovarian cancer claims currently pending across state and federal courts before it can be formally concluded [1].
Erik Haas, J&J's vice president of litigation, framed the offer as a pragmatic business decision rather than an admission of liability. "The allegations are meritless," Haas said in a statement, adding that the proposed resolution "allows the company to put this matter behind it" and enables J&J to "remain focused on its mission to develop medicines and devices that save lives" [1]. He also expressed confidence that the company would have "ultimately prevailed with further litigation" had it chosen to continue fighting in court [1].
Decades of Litigation Over Talc and Asbestos
Lawsuits against J&J over its talc-based baby powder date back to at least 2009 [1]. At the heart of the claims is the allegation that the company's talc products were contaminated with asbestos — a known carcinogen — and that prolonged exposure caused ovarian cancer in thousands of consumers and their survivors [1].
Talc is a naturally occurring mineral composed of magnesium, silicon, oxygen, and hydrogen, prized for its smooth, soapy texture and widely used in personal care products [1]. The concern arises from geology: talc deposits are often found in close proximity to asbestos seams underground, raising the possibility of cross-contamination during mining [1]. J&J has consistently rejected this line of argument, stating that "studies show talc is safe, does not contain asbestos and does not cause cancer" [1].
The legal tide has not run entirely against the company. Earlier in July 2026, a federal court handed J&J a significant procedural victory by questioning individual plaintiffs' ability to demonstrate that talc was the direct cause of their ovarian cancer — a ruling that likely strengthened the company's negotiating position ahead of this settlement offer [1].
From Baby Powder to Cornstarch
J&J's decision to settle comes after the company had already moved to distance itself from talc-based products commercially. The company ended sales of its talc-based baby powder in the United States more than two years before announcing in 2022 that it would discontinue the product globally [1].
"As part of a worldwide portfolio assessment, we have made the commercial decision to transition to an all cornstarch-based baby powder portfolio," the company said at the time [1]. The reformulation effectively acknowledged shifting consumer sentiment, even as J&J maintained that the original product was safe.
Kenvue's Separate Exposure
One notable wrinkle in the settlement's scope is its geographic boundary. J&J's former consumer health division, Kenvue — spun off from the parent company in 2022 — retains liability for Johnson's baby powder sales outside North America [1]. Kenvue owns a portfolio of well-known consumer brands including Band-Aid, Listerine, and Calpol, meaning the talc liability question is not entirely resolved on a global basis [1]. The current $5.5 billion proposal addresses U.S. claims only.
What to Watch Next
Several variables will determine whether this settlement actually closes the chapter. The critical threshold — acceptance by firms representing 95% of claimants — is a high bar, and plaintiffs' attorneys will weigh the per-case value of the offer against the prospects of continued litigation, particularly given the recent federal court ruling that complicated causation arguments [1].
If the 95% threshold is met and the deal is finalized, J&J will have resolved one of the largest and most reputationally damaging product-liability cases in the pharmaceutical industry's recent history. If it falls short, the company faces the prospect of continuing to litigate thousands of individual claims — a costly and unpredictable path, even for a corporation of J&J's scale.
Observers will also be watching whether Kenvue faces parallel pressure to address international talc claims, and how the settlement's payment timeline — with the bulk of funds not flowing until 2028 — affects J&J's financial planning and investor confidence in the quarters ahead.